US Bancorp’s Definium Therapeutics DFTX Stock Holding History

US Bancorp’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.4K	Buy	+1,283	New	+$31.7K	﹤0.01%	2703
2024 Q1	–	Sell	-66	Closed	-$242	–	4051
2023 Q4	$242	Hold	66	–	–	﹤0.01%	3900
2023 Q3	$207	Hold	66	–	–	﹤0.01%	3909
2023 Q2	$236	Hold	66	–	–	﹤0.01%	3916
2023 Q1	$209	Buy	+66	New	+$219	﹤0.01%	4019
2022 Q3	–	Sell	-133	Closed	-$1K	–	4157
2022 Q2	$1K	Hold	133	–	–	﹤0.01%	3975
2022 Q1	$2K	Hold	133	–	–	﹤0.01%	3845
2021 Q4	$3K	Hold	133	–	–	﹤0.01%	3812
2021 Q3	$5K	Buy	+133	New	+$5.75K	﹤0.01%	3649

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

US Bancorp's DFTX Position: Q2 2026 in Review

US Bancorp opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 1,283 shares worth $60.4K. The stake represents ﹤0.01% of the portfolio and ranks #2703 among its holdings. This is a return to the name: US Bancorp previously reported a position in DFTX as recently as Q4 2023.

US Bancorp first reported a position in DFTX in Q3 2021 and has held it in 9 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

US Bancorp held 1,283 shares of Definium Therapeutics worth $60.4K as of Q2 2026.
Definium Therapeutics was a new US Bancorp position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2703 holding.
US Bancorp first reported a position in Definium Therapeutics in Q3 2021 and has held it in 9 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.